Epoch 11: Clinical Productivity Trends

Clinical Study Design, Survival Rates, Cycle Times

Welcome to the 16 NEW Biotech Innovators who have joined us this month! If you haven’t subscribed, join the 1089 researchers, investors, operators, academics, clinicians and entrepreneurs by subscribing here:

Hello Avatar! Welcome back for another week of biotech analysis. This week we discuss Clinical Productivity, a topic that is closely monitored by pharma and clinical research organizations.  Clinical development is a lengthy, expensive process marked by a high failure rate.  Understanding what drives productivity, and more importantly the levers we can pull to improve it are critical to bringing drugs to market in a more cost effective and timely manner.  Today we dig deep into the recent IQUIVA analysis on this topic, analyzing not only a rollup of clinical productivity trends but also the gold-stand metrics of survival and cycle times.

We are now operating under a hybrid subscription model where the Sunday update has moved under the paywall - a BIG THANK YOU to those that have joined. The Thursday market update will continue to remain free. The more forward looking content, the insider insights, and market data you need to really assess what is happening in the world of biotech will shift to Sundays.  

Please help spread the work by subscribing and hitting the share button if you are enjoying our bi-weekly newsletters!

As a reminder, the purpose of the BowTiedBiotech substack is two-fold. Primarily, we aim to provide our scientist audience the tools to build a biotech company and ultimately translate their ideas into medicines for patients.  Secondarily, biotech investors may find this substack useful as we will be providing weekly market updates of the public AND private markets as well as heavily leveraging current financing events as teaching examples.

Go forward we will be making announcements regarding significant public biotech trading opportunities via substack ALERT special posts.  This will focus primarily on the major market moving biotech events and will likely be centered around data readouts from the major scientific conferences.  We will not offer trading advice (and we do not hold any publicly traded biotech equity), but rather flag emerging events that will likely drive stock prices +/-100% in either direction.  Be sure to SUBSCRIBE to not miss.

Enough shilling for the day, lots to cover this week, let's get started!